drugset / Trial / NCT00237133

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

NCT00237133

Phase 4 Completed 112 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)

Timeline

Start
2003-03
Primary completion
2009-01
Completion
2009-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral